Pelthos Therapeutics (PTHS) Interest Expenses (2022 - 2026)
Pelthos Therapeutics (PTHS) posted quarterly Interest Expenses of -$1.4 million for Q4 2025, down 1372.22% year-over-year from $108000.0 in Q4 2024, and down 186.8% quarter-over-quarter from $1.6 million in Q3 2025.
Pelthos Therapeutics (PTHS) Interest Expenses (2022 - 2026) Analysis & Trends
Pelthos Therapeutics' Interest Expenses history runs 4 years deep, the most recent figure standing at -$1.4 million for Q4 2025.
- In Q4 2025, Interest Expenses fell 1372.22% year-over-year to -$1.4 million; the TTM figure through Dec 2025 stood at -$1.2 million (down 196.19% YoY), while the FY2025 annual figure was $25.9 million, up 542.51% from the prior year.
- Interest Expenses for Q4 2025 stood at -$1.4 million, down from $1.6 million in the prior quarter.
- The five-year high for Interest Expenses was $1.9 million in Q4 2022, with the low at -$1.4 million in Q4 2025.
- The 4-year median for Interest Expenses is $105529.0 (2024), against an average of $294896.6.
- The sharpest annual moves came in 2024 and 2025: Interest Expenses soared 1244.78% in 2024, then sank 1372.22% in 2025.
- Pelthos Therapeutics' Interest Expenses stood at $1.9 million in 2022, then slumped by 97.81% to $40708.0 in 2023, then surged by 165.3% to $108000.0 in 2024, then tumbled by 1372.22% to -$1.4 million in 2025.
- Business Quant data shows PTHS's Interest Expenses at -$1.4 million in Q4 2025, $1.6 million in Q3 2025, and $103058.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 39.74 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 82.05 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -4.89 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 20.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 93.62 Mn |
| 10 | Pelthos Therapeutics | 91.09 Mn | 66.53 Mn | 21.23 Mn | 4.74 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.74 Mn |
| Jun 30, 2026 | 4.74 Mn |
| Dec 31, 2025 | -1.37 Mn |
| Dec 31, 2025 | -1.37 Mn |
| Sep 30, 2025 | 1.58 Mn |
| Sep 30, 2025 | 1.58 Mn |
| Jun 30, 2025 | 103,058.00 |
| Jun 30, 2025 | 103,058.00 |
| Mar 31, 2025 | 11,250.00 |
| Mar 31, 2025 | 11,250.00 |
| Dec 31, 2024 | 108,000.00 |
| Dec 31, 2024 | 108,000.00 |
| Sep 30, 2024 | 363,091.00 |
| Sep 30, 2024 | 363,091.00 |
| Jun 30, 2024 | 363,091.00 |
| Jun 30, 2024 | 363,091.00 |
| Mar 31, 2024 | 363,091.00 |
| Mar 31, 2024 | 363,091.00 |
| Dec 31, 2023 | 40,708.00 |
| Dec 31, 2023 | 40,708.00 |